trending Market Intelligence /marketintelligence/en/news-insights/trending/wSggQI-bRU9WcAiPktNzKQ2 content esgSubNav
In This List

Qiagen sells NeXtal Biotechnologies unit to Calibre Scientific

Blog

Insight Weekly: M&A outlook; US community bank margins; green hydrogen players' EU expansion

Blog

Global M&A by the Numbers: Q2 2022

Blog

Insight Weekly: US bank M&A; low refinancing eases rates impact; Texas crypto mining booms

Blog

Infographic 2022 Top Tech Trends Shaping Corporations


Qiagen sells NeXtal Biotechnologies unit to Calibre Scientific

Los Angeles-based Calibre Scientific Inc. acquired Qiagen NV's NeXtal Biotechnologies unit, which specializes in producing protein crystallization plates and screens.

NeXtal's products are sold in the academic, biotechnology and pharmaceutical markets and are used to study the molecular structure of a protein, primarily for creating certain medicines including cancer treatments.

Calibre Scientific CEO Ben Travis said NeXtal's proprietary products complement its offerings.

Financial details of the transaction were not disclosed.

NeXtal Biotechnologies was acquired by Qiagen in 2005 for $14.2 million.